Male Breast Cancer Global Alliance Honors Two
Champions of Survivorship, Advocacy, and Recovery
In a spirited and highly meaningful
leadership meeting, the Male Breast Cancer Global
Alliance (MBCGA) formally recognized two distinguished men whose lives
and work embody courage, compassion, and action in the cancer survivorship
movement: Scott Baker and Dr. Jay Harness.
Hosted by MBCGA President and CEO Cheri Ambrose, the virtual gathering brought
together voices from medicine, publishing, advocacy, and survivorship to
celebrate the appointments of these two men into key leadership roles. Lennard Goetze moderated the event, while
emphasizing a new and growing mission: the launch of a broader movement focused
on Male Breast Cancer Rehabilitation and Restorative Care.
Leadership
Appointments Rooted in Service
The meeting opened with Cheri
Ambrose announcing that Dr. Harness had been invited to join the MBCGA Medical
Advisory Board, an invitation he warmly accepted. His decades of
surgical oncology leadership, global reputation, and groundbreaking advocacy
for exercise oncology made him an ideal addition to the organization’s
expanding medical team.
Soon after, Scott Baker was
officially invited to serve as Community Outreach Ambassador,
recognizing his tireless grassroots support of patients, survivors, and
families navigating the cancer journey. Baker also received notice of a special
award to be presented later in the season for his humanitarian volunteerism and
bedside advocacy.“These appointments
are based on merit, achievements, and proven volunteerism,” Ambrose noted. “We
need leaders who understand survivorship not only professionally—but
personally.”
Nomination
of 2026 Leaders in Survivorship
Though unable to attend the meeting
because of active patient-care responsibilities, Dr.
Robert Bard was repeatedly acknowledged as the principal force behind
the nomination of both honorees. Even in his absence, his presence was strongly
felt throughout the discussion, as speakers referenced his judgment,
leadership, and unwavering commitment to advancing survivorship through
meaningful action. Those who know Bard understand that he does not offer
endorsements casually. When he supports an individual for leadership, it is
rooted in observed merit, measurable contribution, and a genuine belief that
the person can elevate the mission.
Lennard Goetze explained that Bard “hands down” championed the appointment
of Dr. Jay Harness to the Medical Advisory
Board. Bard recognized in Dr. Harness not only an accomplished surgeon and
respected international authority, but also a physician who has continued to
serve long after retirement through education, mentorship, and public advocacy.
In particular, Bard admired Harness’s tireless promotion of exercise oncology—a
field transforming how clinicians view movement, strength, and rehabilitation
during the cancer journey. To Bard, this was not simply a wellness topic; it
was an essential component of modern survivorship medicine.
At the same time, Bard strongly supported the induction of Scott Baker into a leadership role in community
outreach. Baker’s value, in Bard’s eyes, comes from something no credential
alone can provide: lived experience forged through repeated battles with
cancer. Bard has long respected survivors who turn pain into purpose, and
Baker’s willingness to guide others, encourage patients, and stand beside those
in fear represented exactly the kind of servant leadership the organization
seeks. His compassion is practical, credible, and deeply human.
Together, these nominations reveal Bard’s broader philosophy of care. He
believes the future of oncology must go beyond removing tumors or completing
treatment protocols. True victory includes helping patients reclaim strength,
dignity, confidence, mobility, emotional stability, and hope. In Dr. Harness,
Bard saw the science and strategy of survivorship. In Scott Baker, he saw the
heart and humanity of survivorship. By advancing both men, Bard effectively
endorsed a new model of cancer leadership—one where medicine and mentorship
stand side by side, and where quality of life is recognized as the next
frontier of healing.
ExerciseOncologyTakesCenter Stage
One of the most compelling and
forward-looking themes of the meeting was the rising importance of exercise
oncology—a rapidly expanding discipline grounded in scientific
evidence that uses movement, resistance training, cardiovascular conditioning,
and guided physical activity to improve outcomes for people living with and
recovering from cancer. What was once dismissed as a secondary lifestyle
suggestion is now being recognized as an essential pillar of supportive cancer
care. Throughout the discussion, participants made it clear that survivorship
cannot be fully addressed without confronting the physical decline, fatigue,
weakness, emotional strain, and loss of function that so often follow diagnosis
and treatment.
At the center of this conversation was Dr. Jay
Harness, who spoke with conviction about more than thirty years of
accumulating research demonstrating that exercise can positively influence
clinical outcomes across multiple cancer populations. His remarks reflected
both scientific authority and practical wisdom. He emphasized that the data are
no longer speculative or fringe. Study after study has shown that properly
guided exercise can improve stamina, preserve lean muscle mass, reduce
treatment-related fatigue, enhance emotional well-being, support metabolic
health, and help many patients tolerate therapies more effectively.
“Exercise is medicine,” he stated. That phrase became one of the defining
messages of the meeting. Dr. Harness explained that movement creates a cascade
of beneficial physiologic responses throughout the body. Exercise can stimulate
immune surveillance, improve circulation, enhance oxygen delivery to tissues,
and support glucose regulation and insulin sensitivity. It can help counter the
deconditioning that often accompanies chemotherapy, radiation, surgery,
hormonal therapy, or prolonged inactivity. In many ways, it represents a
therapeutic intervention hiding in plain sight.
He further noted that the benefits are not only muscular or cardiovascular.
Physical activity activates powerful neurochemical responses that can directly
influence morale and mental health. Endorphins, dopamine, serotonin, and other
so-called “happy hormones” can elevate mood, reduce anxiety, and restore a
sense of motivation at a time when many survivors feel emotionally depleted.
Yet Dr. Harness stressed that these feel-good effects are only one part of a much
larger biological story. Exercise also impacts inflammatory pathways, cellular
signaling systems, mitochondrial efficiency, and other mechanisms linked to
healing, resilience, and recovery.
As founder of Cancer Fitness, Dr.
Harness has become an influential voice helping patients, clinicians, and
advocacy groups rethink what rehabilitation can look like after cancer. His
mission is not simply to encourage people to move more—it is to help integrate
structured, intelligent movement into the cancer care continuum itself.
The meeting made one point unmistakably clear: exercise is no longer an
optional side note in survivorship. It is becoming a frontline strategy for
restoring strength, confidence, independence, and quality of life.
Scott
Baker: Survivor Wisdom with Real-World Truth
If Dr. Harness represented the
scientific case for survivorship movement, Scott Baker represented the human
case. A four-time cancer survivor, Baker spoke candidly about the emotional
barriers many men face when illness strips away independence.
“There’s nothing wrong with asking
for help,” he said. “It doesn’t make you weak.” He noted that many men avoid
support groups, rehab programs, and public discussion because they wrongly
associate vulnerability with weakness. Yet his own journey taught him that
healing begins when pride ends.
One of the most memorable lines of
the meeting came when Baker said: “It’s hard to be macho when you’re walking
around in a backless hospital gown.” The comment brought laughter—but also
truth. Cancer humbles everyone. Baker’s honesty and humor illustrated exactly
why MBCGA leaders saw him as a model spokesperson for men who need permission
to seek support.
Challenging
Bias Around Male Breast Cancer
Another major topic was the ongoing
stigma surrounding male breast cancer itself. Goetze emphasized that male
breast cancer remains underdiagnosed partly because many men do not want to
acknowledge symptoms, undergo screening, or publicly discuss a disease
culturally labeled as female.
“Stop the bias” has become a
rallying message for MBCGA. The organization believes earlier detection, public
education, and open conversations can save lives. Baker and Harness were
praised as the kind of visible male leaders who can help dismantle silence and
embarrassment.
A
New Movement: Rehabilitation and Restoration
Goetze also introduced a new
strategic segment under the MBCGA umbrella: Male Breast Cancer Rehab
and Restorative Movement. This initiative promotes a broader
understanding of survivorship—not merely living after treatment, but living
well after treatment. That means attention to:
strength
rebuilding
fatigue
recovery
emotional
resilience
body
confidence
hormonal
health
social
connection
exercise
programming
return
to purpose and identity
As Ambrose said during the
discussion, many survivors are searching for “some sense of normal”—even if it
becomes a “new normal.”
A
Global Future
Dr. Harness also accepted an
invitation to speak at the MBCGA Global Medical Summit this October, further
strengthening ties between the alliance and the worldwide exercise oncology
movement. Participants discussed future podcasts, publishing collaborations,
firefighter outreach programs, advocacy campaigns, and cross-promotional
education that can bring survivorship tools to more people internationally.
Conclusion
This was more than an appointment
meeting—it was a declaration of direction. By inducting Scott Baker and Dr. Jay
Harness into leadership, the Male Breast Cancer Global Alliance signaled that
the future of cancer advocacy must include not only awareness and treatment—but
rehabilitation, exercise, emotional healing, and restored quality of life. Two
men were honored. But countless survivors stand to benefit.
Beyond Survival A Cardiologist’s Perspective with Dr. Hwaida Hannoush
By: Lennard Goetze, Ed.D | Daniel Root | Regina Bessler, PhD
In an era when medicine is becoming increasingly specialized, few physicians
are as committed to bridging disciplines as Dr. Hwaida Hannoush, a cardiologist and functional
medicine practitioner whose work reflects the growing need for more
personalized, predictive, and preventive care. As the founder of Precimed Clinic, Dr. Hannoush
has built her clinical philosophy around one central belief: that precision medicine must be at the heart of
modern healthcare.
With a strong focus on women’s
heart health, preventive cardiology, and individualized
treatment strategies, Dr. Hannoush combines the rigor of traditional
cardiovascular medicine with the systems-based insight of functional medicine.
Her approach is rooted in uncovering the deeper drivers of disease rather than
simply managing symptoms. At Precimed Clinic, that means using advanced
diagnostics, nuanced interpretation, and personalized care plans to help
patients understand the “why” behind their cardiovascular risk—and, where possible,
reverse it.
But in a recent discussion about cancer rehabilitation and survivorship, Dr.
Hannoush turned her attention to a topic that remains dangerously
under-recognized in mainstream medicine: the cardiovascular consequences of cancer therapy. Her
message was clear, urgent, and clinically significant: for many cancer survivors, the battle does
not end when the tumor is gone.
The Overlooked Crisis in
Cancer Survivorship
Much of the public conversation around cancer treatment centers on
remission, recurrence, and tumor response. But according to Dr. Hannoush, there
is another threat quietly affecting survivors long after treatment has ended: cardiovascular injury. “I want to highlight,” she said, “that for
many cancer survivors, cardiovascular side effects of chemotherapy become a
serious — and often unrecognized — long-term threat.” That observation reframes
the survivorship conversation in an important way.
While cancer therapies are often life-saving, many of them can place
profound stress on the cardiovascular system. These effects may not always be
immediately visible, but over time they can contribute to heart failure, arrhythmias, coronary disease,
vascular dysfunction, metabolic injury, and long-term decline in physical
resilience. Research
shows that as cancer treatments become more effective and survival extends,
cardiovascular disease increasingly emerges as a dominant competing risk —
underscoring why protecting the heart during and after cancer treatment is not
optional, but essential.
This is the domain of cardio-oncology,
an evolving field focused on protecting heart health before, during, and after
cancer treatment. Dr. Hannoush has seen its importance firsthand, particularly
through her previous work evaluating heart function in patients undergoing
aggressive therapies.
She explained that this is not a fringe concern or a rare side effect. In
many cases, cardiovascular
complications become the dominant long-term health threat in cancer survivors,
particularly when these patients are not proactively monitored.What
sets Dr. Hannoush apart from many cardiologists is that she brings a second,
complementary lens to this work: functional medicine. While cardio-oncology
guidelines focus on monitoring heart function, managing cardiovascular risk
factors, and intervening when damage is detected, functional medicine asks a
deeper upstream question — why is this particular patient’s body uniquely
vulnerable, and what can be done to strengthen its resilience before and after
treatment begins? It is the integration of both frameworks that defines her
approach to survivorship care.
Why the Heart Is So
Vulnerable
One of the strengths of Dr.
Hannoush’s perspective is her ability to explain cardiac injury not as a single
event, but as a multi-layered biological
process.
According to her, chemotherapy and related treatments can harm the
cardiovascular system through several overlapping mechanisms. First, some drugs
can cause direct injury to the
myocardium, the muscular tissue of the heart itself. Others
disrupt the mitochondria,
the energy-producing structures that are especially abundant in cardiac tissue.
“The heart is rich in mitochondria,” she explained, “which is the power
source.”
When mitochondrial function is impaired, the heart may continue beating, but
it does so with reduced cellular efficiency and diminished reserve.Research
confirms that drugs like doxorubicin cause mitochondrial oxidative stress,
impaired energy production, and accelerated cell death in cardiac tissue — and
that a patient’s individual mitochondrial biology can influence how vulnerable
their heart is to this damage, pointing toward a future of more personalized
cardiac risk assessment.
Cancer treatments can also affect the coronary arteries, promoting atherosclerosis and
increasing the risk of infarction or heart attack. At the same time, they may
alter glucose regulation,
insulin sensitivity, lipid metabolism, oxidative stress, and inflammatory
burden—all of which increase cardiovascular risk even further.
Dr. Hannoush also emphasized the role of hormonal disruption, especially in therapies that
suppress sex hormones. In both women and men, these hormonal shifts can have
significant effects on vascular function, metabolism, and heart health. And perhaps
most compellingly, she pointed to a mechanism often left out of conventional
oncology conversations: the gut-heart
axis.
“Gut dysbiosis is a very important side effect of chemotherapy,” she said.
Because gut health influences inflammation, immune regulation, neurotransmitter
production, and metabolic stability, its disruption can have ripple effects far
beyond digestion. Emerging preclinical
evidence supports this concern: chemotherapy-induced gut dysbiosis can increase
intestinal permeability, allowing bacterial products to enter the bloodstream
and drive systemic inflammation that worsens cardiovascular injury — a pathway
now being studied as part of the gut-microbiota-heart axis. While direct proof
in humans is still developing, the mechanistic evidence is compelling and
growing.
One cardiovascular risk that
deserves particular mention — especially for readers who have undergone
treatment for breast cancer, Hodgkin lymphoma, or lung cancer — is radiation
therapy. When radiation involves the chest, it can damage the coronary
arteries, heart valves, and the pericardial sac through a process of chronic
inflammation and scarring. What makes this especially difficult to detect is
that these effects can remain silent for years or even decades after treatment
ends. Long-term survivors who received chest radiation as recently as their
twenties or thirties may not see cardiovascular consequences until midlife —
making awareness and surveillance in this population critically important.
Taken together, these mechanisms reveal a difficult truth: many cancer treatments affect not only the
tumor, but the body’s foundational systems of resilience.
The Problem with Waiting
Too Long
A major concern for Dr. Hannoush is
that conventional monitoring often catches cardiovascular damage too late. Traditionally,
clinicians look for a decline in ejection fraction (EF) ― a measure of how much blood the
heart pumps out with each beat. But by the time EF drops, injury may already be
well underway.
That is why she strongly advocates strain imaging, a more sensitive technique that evaluates
subtle deformation in the heart muscle before overt dysfunction appears. “You
don’t want to wait till the heart function drops,” she explained. “You want to
detect it earlier.”
This technology, commonly referred to as longitudinal strain, has become a valuable tool in
cardio-oncology because it can reveal subclinical deterioration in the myocardium before
symptoms emerge and before standard imaging appears abnormal.
For Dr. Hannoush, this represents one of the clearest examples of what
precision medicine should look like in practice: not reactive care, but early detection, functional monitoring, and
intervention before collapse. She also emphasized that such
monitoring should not be sporadic or incidental. Oncology patients, she argued,
should have structured
cardiovascular protocols that include echocardiograms,
biomarker tracking, and ongoing surveillance tailored to their treatment
exposure.
Cancer Rehab Must Be More
Than Physical Therapy
Another central theme in Dr.
Hannoush’s discussion was the need to redefine what “rehabilitation” actually
means after cancer treatment. From her perspective, true recovery is not limited to mobility or strength
training. It must include the broader restoration of the systems that treatment
may have disrupted—the heart,
skeletal muscle, metabolism, hormones, nutrition, detoxification pathways, and
even the microbiome.
She specifically highlighted skeletal
muscle as a major but often neglected player in survivorship.
“Muscles are very important,” she said, noting that skeletal muscle functions
as a kind of metabolic organ.
It helps regulate insulin sensitivity, glucose uptake, and systemic energy
balance. When cancer treatment contributes to muscle loss or frailty, the
patient does not just become weaker—they become metabolically more vulnerable.What is perhaps most striking is that this
vulnerability extends directly to the heart itself. Research shows that
chemotherapy-induced muscle wasting can involve the myocardium — a phenomenon
known as cardiac wasting — which thins the ventricular wall, raises cardiac
stress, and can contribute to arrhythmias and heart failure independently of
the direct toxic effects of the drugs. Protecting skeletal muscle and
protecting the heart, it turns out, are not separate goals.
That is one reason why she sees rehabilitation as something far broader than
conventional exercise recovery. It must also include metabolic rebuilding, nutrient replenishment,
and resilience restoration.
One Size Does Not Fit All
Perhaps the most defining principle
in Dr. Hannoush’s philosophy is her insistence that no two patients should be treated as
biologically identical. “One size does not fit all,” she said
plainly. That statement applies not only to cancer treatment, but to what comes
after it.
This is where Dr. Hannoush’s
functional medicine training becomes most distinct. Standard cardio-oncology
guidelines — supported by major cardiac societies — focus on monitoring
ejection fraction and strain, managing blood pressure and cholesterol, and
initiating medications when cardiovascular risk is identified. These are
essential and evidence-based. But functional medicine, as practiced by Dr.
Hannoush, asks what lies beneath those numbers: What is this patient’s
individual metabolic reserve? How are they processing and eliminating the
chemical burden of treatment? What nutritional or hormonal imbalances are
amplifying their vulnerability? These questions, she believes, are just as
important as the clinical measurements and often go unasked.
In her view, survivorship care should be personalized using tools such as:
Nutrigenomics
Pharmacogenomics
Metabolomics
Advanced nutrient and
functional testing
Individualized detoxification
assessment
Cardiovascular and metabolic
monitoring
This is especially important because two patients can receive the same
therapy and emerge with dramatically different outcomes depending on their
baseline reserves, detoxification capacity, nutrient status, hormonal balance,
and metabolic health. “It’s not only about the outside toxins,” she noted.
“Chemotherapy is one of the toxins, of course. And you need to know how your
body is able to detoxify.”
That perspective — grounded in
functional medicine’s core principle of identifying root causes rather than
managing symptoms — broadens the survivorship conversation in an important way.
Rather than viewing side effects as unavoidable collateral damage, Dr. Hannoush
challenges clinicians to ask a more useful question: what can be measured, supported, and
personalized before the damage becomes permanent?
An Awareness Gap That Must
Be Closed
Dr. Hannoush also noted that the field still
carries significant blind spots — and that women are among those most affected
by them. Sex and racial differences in how cancer therapies damage the heart
remain poorly understood, and most foundational cardio-oncology research has
not been designed with these differences in mind. Women who have undergone
treatment for breast cancer — many of whom received anthracycline-based
chemotherapy, HER-2 inhibitors, aromatase inhibitors, or chest radiation
represent a large and growing population of survivors with elevated
cardiovascular risk. Yet the evidence base to guide their care remains incomplete. For readers of this publication,
that gap is not abstract: it is personal. Advocating for thorough
cardiovascular surveillance after cancer treatment is not overcaution: it is
self-knowledge
Despite the growing evidence in
support of cardio-oncology and personalized survivorship care, Dr. Hannoush
believes one of the greatest barriers is still lack of awareness. Many patients are never fully informed
about what to watch for after treatment. Some assume that once chemotherapy is
complete, the danger has passed. Others may not connect symptoms like fatigue,
exercise intolerance, palpitations, weight gain, or metabolic instability to
prior treatment exposure.
That silence, she suggests, is part of the problem. For now, she believes
the most realistic first step is not perfection—it is education. “Raising awareness
will be good as a start,” she said.
That awareness must extend to patients, caregivers, oncologists,
cardiologists, and the broader rehab community. Because if survivorship is
truly the goal, then medicine must stop measuring success only by tumor
shrinkage and begin asking a more complete question:
What did the treatment
save—and what did it cost? In that conversation, Dr. Hwaida
Hannoush offers a voice that is both scientifically grounded and clinically
humane. Her work reminds the medical world that surviving cancer should not
mean silently inheriting a second chronic disease. If precision medicine is truly the future, then survivorship care must
become just as precise.
Dr. Hwaida Hannoush is a board-certified cardiologist recognized for her work in women’s cardiovascular health, metabolic medicine, and healthy aging. She blends evidence-based cardiology with preventive and functional strategies to help patients protect heart health while improving long-term vitality. Her clinical focus explores how inflammation, insulin resistance, hormonal changes, stress, and lifestyle patterns influence cardiovascular risk—particularly in women and adults navigating midlife transitions. Known as both a physician and educator, Dr. Hannoush promotes early detection, personalized care, and multidisciplinary collaboration that integrates nutrition, endocrinology, and wellness principles to support stronger hearts and longer, healthier lives.
References
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M., Bergler-Klein, J., ... & ESC Scientific Document Group. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. European Heart Journal, 43(41), 4229–4361. https://doi.org/10.1093/eurheartj/ehac244
Camilli, M., Del Buono, M. G., Sanna, T., & Abbate, A. (2024). Anthracycline cardiotoxicity in adult cancer patients: JACC state-of-the-art review. JACC: CardioOncology, 6(5), 643–660. https://doi.org/10.1016/j.jaccao.2024.07.016
Koutsoukis, A., Ntalianis, A., Repasos, E., Kastritis, E., Dimopoulos, M. A., & Paraskevaidis, I. (2018). Cardio-oncology: A focus on cardiotoxicity. European Cardiology Review, 13(1), 64–69. https://doi.org/10.15420/ecr.2018:4:2
Dobson, R., Ghosh, A. K., Ky, B., Marwick, T., Stout, M., Harkness, A., & Senior, R. (2021). British Society of Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab. JACC: CardioOncology, 3(1), 1–16. https://doi.org/10.1016/j.jaccao.2021.01.011
Belger, C., Friedmann Angeli, J. P., & Bruns, D. R. (2024). Doxorubicin-induced cardiotoxicity and risk factors. Biomedicine & Pharmacotherapy, 170, 115980. https://doi.org/10.1016/j.biopha.2023.115980
Qiu, Y., Gao, J., Chen, Y., & Wang, J. (2023). Anthracycline-induced cardiotoxicity: Mechanisms, monitoring, and prevention. Frontiers in Cardiovascular Medicine, 10, 1242596. https://doi.org/10.3389/fcvm.2023.1242596
Gent, D. G., Dent, S., & Lyon, A. R. (2023). The 2022 European Society of Cardiology cardio-oncology guidelines: Key messages for clinical practice. Cardiac Failure Review, 9, e18. https://doi.org/10.15420/cfr.2023.08
Bloom, M. W., Herrmann, J., Ky, B., & Lenihan, D. J. (2025). Cardio-oncology and heart failure: A scientific statement from the Heart Failure Society of America. Journal of Cardiac Failure, 31(2), 145–170.
Dempsey, N., Rosenthal, A., Dabas, N., Kropotova, Y., Lippman, M., & Bishopric, N. H. (2021). Trastuzumab-induced cardiotoxicity: A review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Research and Treatment, 188(1), 21–36. https://doi.org/10.1007/s10549-021-06205-8
Mecinaj, A., Gulati, G., Heck, S. L., & Omland, T. (2024). Impact of the ESC cardio-oncology guidelines biomarker criteria in anthracycline-treated breast cancer patients. JACC: CardioOncology, 6(1), 85–97.
Mallidi, J., Lenneman, C., & Herrmann, J. (2024). Management of cancer therapy-related cardiac dysfunction in clinical practice. American Journal of Cardiology, 214, 88–99.
Witteles, R. M., & Telli, M. L. (2022). ESC cardio-oncology guidelines: A triumph—but are we ready for implementation? JACC: CardioOncology, 4(4), 639–642. https://doi.org/10.1016/j.jaccao.2022.10.002
Breast cancer is often perceived as
a woman’s disease—but for thousands of men diagnosed each year, that
misconception creates dangerous gaps in awareness, education, and survivorship
care. One of the most overlooked consequences of treatment—particularly for
men—is what happens after lymph node removal.
While lymph node surgery is
essential for staging and guiding therapy, it can permanently alter the body’s
lymphatic system. The result? A lifelong risk of lymphedema, a condition that
is frequently underdiagnosed, undertreated, and misunderstood—especially in
male patients.
For both men and women, the
conversation must evolve. This is not just about removing cancer. It is about
preserving function, preventing complications, and restoring quality of life.
Why Lymph Nodes Are Removed in
Breast Cancer
Lymph nodes serve as biological
checkpoints—filtering fluid, trapping pathogens, and, critically, capturing
cancer cells that attempt to spread beyond the primary tumor. In breast cancer, the first
destination for migrating cancer cells is often the lymph nodes in the underarm
(axillary region). As outlined in the original reference material , surgeons
remove these nodes to determine whether cancer has spread and to guide
decisions about chemotherapy, radiation, and long-term management.
For men, whose breast tissue is
minimal and whose diagnoses are often delayed, lymph node involvement can be
more common at the time of detection—making node removal even more likely.
The Hidden Aftermath: Lymphedema
When lymph nodes are removed or
damaged, the body loses part of its drainage system. Lymph fluid—rich in
proteins and immune cells—can accumulate in surrounding tissues, leading to
swelling, inflammation, and long-term structural changes. This condition, known as lymphedema,
can affect:
The arm and hand
The chest wall
The back or flank
While often associated with women, men
are equally at risk—and frequently less prepared. Why? Because male breast
cancer patients are rarely given the same level of preoperative education about
lymphatic health. Many are unaware of early warning signs until the condition
has progressed.
Men and Lymphedema: The Awareness
Gap
Male breast cancer represents less
than 1% of all breast cancer cases, but that rarity comes at a cost:
Fewer tailored educational resources
Lower clinical suspicion for complications
Delayed reporting of symptoms
Men may dismiss early swelling as
muscle strain or weight fluctuation. Others may avoid reporting symptoms
altogether, due to stigma or lack of awareness. This is a critical failure point in
survivorship care. Lymphedema does not discriminate by
gender—but education often does.
Surgical Approach Matters
Not all lymph node surgeries carry
the same level of risk.
Sentinel Lymph Node Biopsy (SLNB): Removes only a few key nodes. Lower risk.
Radiation therapy to the lymph node
region can further impair lymphatic flow, increasing the likelihood of
long-term complications. For male patients—who often present with more advanced
disease—ALND is more common, placing them at heightened risk from the outset.
Early Detection: The New Standard
The traditional model—waiting for
visible swelling—is outdated. Today, the goal is early
detection and prevention, using:
This aligns with a broader movement
in modern medicine: identifying dysfunction before it becomes disease.
Prevention Strategies for Men and
Women
1. Arm Protection Is Critical: The affected arm becomes more
vulnerable to infection and inflammation.
Avoid:
Blood draws and injections in that arm
Blood pressure cuffs
Trauma (cuts, burns, heavy strain)
This applies equally to
men—especially those returning to physical labor or fitness routines.
2. Movement Is Non-Negotiable
The lymphatic system depends on
motion.
Recommended:
Gentle range-of-motion exercises post-surgery
Progressive strength training
Daily activity (walking, light resistance work)
Men, in particular, may attempt to
“push through” recovery. The key is progressive—not aggressive—loading.
3. Compression as a Preventative
Tool
Compression garments are not just
reactive—they can be preventative. Use during:
Air travel
Intense physical activity
Early signs of swelling
Proper fitting is essential.
4. Manual Lymphatic Drainage (MLD)
A specialized therapy that helps
reroute lymph fluid.
Benefits:
Reduces swelling
Improves circulation
Maintains tissue integrity
Often underutilized in male patients
due to lack of referral.
5. Weight and Metabolic Health: Higher body mass is associated with
increased lymphedema risk.
A structured approach to:
Nutrition
Body composition
Inflammation control is essential for long-term
outcomes.
The Missing Link: REHABILITATION
This is where the conversation must
expand—especially within the mission of the Male Breast Cancer Global Alliance.
Surgery is not the finish line. It is the starting point for rehabilitation. A comprehensive rehab model should
include:
For men, this also means normalizing
the conversation—bringing male breast cancer and its complications out of
the shadows.
Conclusion
Lymph node removal saves lives—but
it also changes lives. For both men and women, the risk of
lymphedema represents a critical intersection between treatment and
survivorship. And for men, the challenge is even greater due to lack of
awareness, delayed education, and limited resources. The solution is clear:
Educate early
Monitor continuously
Rehabilitate aggressively—but intelligently
Breast cancer care must no longer
end when the tumor is removed. It must extend into a structured, proactive
system of recovery—one that protects the lymphatic system, restores physical
function, and honors the full journey of survivorship. Because survival is not
enough. The goal is to return every patient—man or woman—to strength,
movement, and quality of life.
Leadership
Appointments Rooted in Service
Scott
Baker: Survivor Wisdom with Real-World Truth
Challenging
Bias Around Male Breast Cancer
A
Global Future
